In the current study, we presented the novel discovery that CLC-1 degradation is prevented by the Hsp90 inhibitor 17-AAG, which is also being tested in various clinical trials as an anti-cancer agent39, 40, 60. This evidence concerns the gene CLCN1 and cancer.